Search clinical trials for: Sofosbuvir/Velpatasvir/Voxilaprevir

Total 373 results

University of California, San Francisco
Janssen Scientific Affairs, LLC

Withdrawn

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

Hepatitis C, Chronic | HIV CDC Category A1

United States
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

HIV | Hepatitis C Virus

United States, New Zealand, Canada, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Arrowhead Regional Medical Center

Unknown

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Withdrawn

DAA in the Risk of Recurrence After Curative Treatment of HCC

Hepatocellular Carcinoma
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Benha University

Completed

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Male Infertility | HCV

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Hannover Medical School
Gilead Sciences; HepNet Study House, German Liverfoundation; German Center for...

Completed

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Hepatitis E | Hepatitis Chronic Viral

Germany
Bristol-Myers Squibb

Withdrawn

A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)

Hepatitis C

France, Canada
Radboud University Medical Center

Completed

Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole. (COPA)

Hepatitis C | Swallowing Disorder

Netherlands
Janssen Sciences Ireland UC

Completed

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Belgium
Bristol-Myers Squibb

Terminated

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Hepatitis C | Chronic Hepatitis

Australia, Spain
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Gilead Sciences

Completed

Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea

Hepatitis C Virus

Korea, Republic of
Beni-Suef University

Completed

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Chronic Hepatitis C Virus Infection
Janssen Research & Development, LLC

Completed

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (ACCORDION-1)

Hepatitis C Virus

United States, Canada
Genuine Research Center, Egypt
Multi-Apex Pharma

Completed

A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Healthy

Egypt
Cairo University

Unknown

Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19

COVID-19
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
Ottawa Hospital Research Institute
Gilead Sciences; CIHR Canadian HIV Trials Network

Completed

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (CTN289)

Hepatitis C, Chronic | Human Immunodeficiency Virus

Canada
Ginkgopharma CO., LTD

Unknown

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients

Hepatitis C Virus Infection

China
PharmEvo Pvt Ltd

Completed

Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (HEATS)

Hepatitis C, Chronic

Pakistan
Kawin Technology Share-holding Co., Ltd.
KawinGreen Biotech Co., Ltd.

Completed

Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C (KW-136_II)

Hepatitis C, Chronic

China
Bristol-Myers Squibb

Completed

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV (ALLY 3)

Hepatitis C

United States, Puerto Rico
Genuine Research Center, Egypt
Pharmed Healthcare, Egypt

Completed

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Healthy

Egypt
University of Dundee

Completed

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (ADVANCE)

Hepatitis C

United Kingdom
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Ginkgopharma CO., LTD

Unknown

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients

Hepatitis C Virus Infection

China
Kawin Technology Share-holding Co., Ltd.
KawinGreen Biotech Co., Ltd.

Completed

KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C (KW-136_III)

Hepatitis C, Chronic

China
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

HCV Infection

United States, France, Australia, Puerto Rico, Spain
ANRS, Emerging Infectious Diseases

Completed

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa (TAC)

HIV Infection | Hepatitis C

Cameroon, Côte D'Ivoire, Senegal
Zagazig University
Cairo University

Unknown

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Hepatitis C
University Hospital, Geneva
Gastaldi Giacomo; Clément Sophie

Completed

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Insulin Resistance

Switzerland
Novartis

Withdrawn

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis (INSURE)

Uveitis

Israel, United States, Switzerland, Canada, Japan
Bristol-Myers Squibb

No longer available

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Open-Label Hepatic Impairment Study

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Ain Shams University

Completed

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

Metabolic Syndrome | Chronic Hepatitis c

Egypt

3

Subscribe